Warm Springs Advisors Inc. Sells 96 Shares of Thermo Fisher Scientific Inc. $TMO

Warm Springs Advisors Inc. cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the 2nd quarter, Holdings Channel reports. The firm owned 3,906 shares of the medical research company’s stock after selling 96 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.4% of Warm Springs Advisors Inc.’s holdings, making the stock its 22nd largest holding. Warm Springs Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $1,584,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Cornerstone Planning Group LLC increased its holdings in Thermo Fisher Scientific by 105.0% during the first quarter. Cornerstone Planning Group LLC now owns 123 shares of the medical research company’s stock worth $61,000 after buying an additional 63 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in Thermo Fisher Scientific by 1.7% in the first quarter. Rehmann Capital Advisory Group now owns 2,447 shares of the medical research company’s stock valued at $1,218,000 after acquiring an additional 42 shares during the last quarter. Finally, Quotient Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 25.5% during the 1st quarter. Quotient Wealth Partners LLC now owns 1,245 shares of the medical research company’s stock valued at $619,000 after acquiring an additional 253 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of several research analyst reports. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a report on Wednesday, October 8th. Wells Fargo & Company upped their price objective on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $566.47 on Friday. The business has a 50-day simple moving average of $516.99 and a 200 day simple moving average of $461.35. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a market cap of $212.83 billion, a price-to-earnings ratio of 32.73, a PEG ratio of 3.27 and a beta of 0.82. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the completion of the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This trade represents a 1.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 36,420 shares of company stock worth $19,980,884. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.